About this trial
Propofol has a rapid onset and short duration of action, making it widely used for induction of general anesthesia. However, its prominent drawback is circulatory depression. Our research team previously proposed an individualized dosing method for the titration of propofol. We then compared the effects of different titration rates of propofol on hemodynamics and stress during general anesthesia induction. It was found that the incidence of hypotension during the induction period was lower in the 0.5 mg/kg/min group, with lower stress levels and faster postoperative recovery. However, this group still had a 25.3% incidence of hypotension. Therefore, we plan to further study the differences in hemodynamics, depth of anesthesia, stress response, and postoperative recovery in three groups of patients induced with a constant infusion rate of propofol at 0.5 mg/kg/min titrated to an OAA/S score of 1, an OAA/S score of 2, and BIS ≤ 60, combined with remifentanil 2 μg/kg. This study aims to explore the appropriate propofol titration endpoint during general anesthesia induction to maintain stable perioperative haemodynamics and achieve rapid postoperative recovery.
Eligibility criteria
Qualifiers
Age 18-60 years.
Elective surgery with planned endotracheal intubation under general anesthesia.
ASA classification of I or II,with heart function classified as 1 or 2.
Body Mass Index (BMI) 18-30 kg/m².
Disqualifiers
Severe cardiac, pulmonary, hepatic, or renal diseases (heart function classification greater than 3 / respiratory failure / liver failure / renal failure).
Malignant arrhythmias: atrial flutter, atrial fibrillation, atrioventricular block, frequent ventricular premature beats, multifocal ventricular premature beats, ventricular premature beats R on T, ventricular flutter, and ventricular fibrillation.
Expected difficulty with intubation, hypoalbuminemia, hypertension, or diabetes mellitus.
Patients with a high risk of aspiration due to a full stomach, gastrointestinal obstruction, or pregnancy.
Trial design
Treatments tested in this trial
- Titrated administration of propofol to an OAA/S score of 1 as the endpoint
- Titrated administration of propofol to an OAA/S score of 2 as the endpoint
- Titrated administration of propofol to a BIS value ≤ 60 as the endpoint
Treatment groups
Sponsors and collaborators
SanQing Jin
Lead sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Sponsor institution